Psilera receives NIH milestone-driven grant for PSIL-006 in frontotemporal dementia — $2M over 3 years
Summary
Psilera announced receipt of a 3-year milestone-driven grant from the National Institutes of Health worth up to $2 million in October 2025 for their lead program PSIL-006 — a next-generation neuroplastogen for the treatment of frontotemporal dementia (FTD). The grant funds preclinical development and was awarded alongside Psilera's collaboration with Hesperos for advanced preclinical modeling of PSIL-006 in FTD. Psilera also hosted the first annual Frontotemporal Dementia Research Summit in January 2025, establishing themselves as a convener of the FTD research community.
Why it matters
Frontotemporal dementia is the most common dementia in adults under 65 and has no approved disease-modifying treatments. NIH grant funding for a neuroplastogen approach to FTD is scientifically significant — it means NIH peer reviewers believe the neuroplasticity mechanism has merit for a disease characterized by synaptic and neuronal loss in frontal and temporal lobes. If PSIL-006 produces neuroplasticity in FTD models, it would be the first pharmacological approach with mechanistic rationale in this devastating condition.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial